UA116480C2 - Похідна біфенілу та спосіб її одержання - Google Patents

Похідна біфенілу та спосіб її одержання

Info

Publication number
UA116480C2
UA116480C2 UAA201601871A UAA201601871A UA116480C2 UA 116480 C2 UA116480 C2 UA 116480C2 UA A201601871 A UAA201601871 A UA A201601871A UA A201601871 A UAA201601871 A UA A201601871A UA 116480 C2 UA116480 C2 UA 116480C2
Authority
UA
Ukraine
Prior art keywords
disease
preparation
isomers
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
UAA201601871A
Other languages
English (en)
Inventor
Сон-Хвє Кім
Вон-Пін Ім
Чхон-Хван ЧХО
Сун-Хо ЧХОЙ
Чун-Сан ПАК
Мі-Йон Кім
Сун-Хак ЧХОЙ
Мін-Чун Лі
Кан-Хун ЧХО
Original Assignee
Донг-А Ст Ко., Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Донг-А Ст Ко., Лтд filed Critical Донг-А Ст Ко., Лтд
Publication of UA116480C2 publication Critical patent/UA116480C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Даний винахід стосується похідних біфенілу, їхніх ізомерів або їхніх фармацевтично прийнятних солей, способів їхнього одержання та фармацевтичних композицій, що містить вищевказане. Похідні біфенілу, їхні ізомери або їхні фармацевтично прийнятні солі, як розкрито в даному винаході, слугують антагоністом мускаринового M3-рецептора та, таким чином, придатні для попередження або лікування захворювання, вибраного з групи, що включає хронічну обструктивну хворобу легень, астму, синдром подразненої товстої кишки, нетримання сечі, риніт, спазматичний коліт, хронічний цистит, хворобу Альцгеймера, сенільну деменцію, глаукому, шизофренію, гастроезофагеальну рефлюксну хворобу, аритмію серця та синдроми гіперсалівації.
UAA201601871A 2013-07-30 2014-07-17 Похідна біфенілу та спосіб її одержання UA116480C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020130090175A KR101538846B1 (ko) 2013-07-30 2013-07-30 신규한 바이페닐 유도체 및 그의 제조방법
PCT/KR2014/006483 WO2015016511A1 (ko) 2013-07-30 2014-07-17 신규한 바이페닐 유도체 및 그의 제조방법

Publications (1)

Publication Number Publication Date
UA116480C2 true UA116480C2 (uk) 2018-03-26

Family

ID=52431993

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201601871A UA116480C2 (uk) 2013-07-30 2014-07-17 Похідна біфенілу та спосіб її одержання

Country Status (20)

Country Link
US (1) US9828339B2 (uk)
EP (1) EP3029026B1 (uk)
JP (1) JP6109425B2 (uk)
KR (1) KR101538846B1 (uk)
CN (1) CN105555761B (uk)
AU (1) AU2014297144B2 (uk)
CA (1) CA2919624C (uk)
ES (1) ES2710389T3 (uk)
HK (1) HK1218755A1 (uk)
IL (1) IL243830B (uk)
MX (1) MX366639B (uk)
MY (1) MY175411A (uk)
PH (1) PH12016500197A1 (uk)
PT (1) PT3029026T (uk)
RU (1) RU2644234C2 (uk)
SG (1) SG11201600624RA (uk)
TR (1) TR201901449T4 (uk)
UA (1) UA116480C2 (uk)
WO (1) WO2015016511A1 (uk)
ZA (1) ZA201601227B (uk)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034535C (en) * 2016-08-26 2021-07-06 Dong-A St Co., Ltd. Novel salt of (r)-(1-methylpyrrolidine-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and a crystal form thereof
KR102239776B1 (ko) 2016-08-26 2021-04-13 동아에스티 주식회사 (r)-(1-메틸피롤리딘-3-일)메틸(3'-클로로-4'-플루오로-[1,1'-비페닐]-2-일)카바메이트의 신규염 및 이의 결정형
KR102611847B1 (ko) * 2023-03-27 2023-12-12 주식회사 이플라스크 무스카린 수용체 길항 활성을 갖는 신규한 피롤리디늄 화합물 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1140447A (zh) * 1994-02-10 1997-01-15 山之内制药株式会社 新的氨基甲酸酯衍生物及其药物组合物
WO1995021820A1 (fr) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
US5613402A (en) * 1995-06-06 1997-03-25 Itt Automotive, Inc. Adjustable set bearing
EP1235802B1 (en) 1999-12-07 2005-07-13 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1781607A2 (en) 2004-08-19 2007-05-09 Ranbaxy Laboratories Limited Pyrrolidine derivatives as muscarinic receptor antagonists
US20090012116A1 (en) * 2005-07-11 2009-01-08 Naresh Kumar Muscarinic Receptor Antagonists
SI1928821T1 (sl) * 2005-09-21 2009-04-30 Pfizer Ltd Derivati karboksamida kot antagonisti muskarinskih receptorjev
JP5293192B2 (ja) * 2007-02-09 2013-09-18 アステラス製薬株式会社 アザ架橋環化合物
UA100983C2 (uk) 2007-07-05 2013-02-25 Астразенека Аб Біфенілоксипропанова кислота як модулятор crth2 і інтермедіати
KR101341692B1 (ko) 2011-03-16 2013-12-20 동아에스티 주식회사 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물
KR101341693B1 (ko) 2011-03-16 2013-12-16 동아에스티 주식회사 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물
KR101457789B1 (ko) 2013-02-13 2014-11-03 동아제약 주식회사 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법

Also Published As

Publication number Publication date
CA2919624A1 (en) 2015-02-05
CN105555761A (zh) 2016-05-04
US9828339B2 (en) 2017-11-28
ZA201601227B (en) 2017-11-29
KR101538846B1 (ko) 2015-07-22
EP3029026B1 (en) 2018-12-05
EP3029026A4 (en) 2017-01-11
EP3029026A1 (en) 2016-06-08
HK1218755A1 (zh) 2017-03-10
JP2016525571A (ja) 2016-08-25
MY175411A (en) 2020-06-24
AU2014297144B2 (en) 2017-06-08
PT3029026T (pt) 2019-02-06
BR112016001746A2 (pt) 2017-08-01
MX366639B (es) 2019-07-17
RU2016106977A (ru) 2017-09-01
RU2644234C2 (ru) 2018-02-09
PH12016500197B1 (en) 2016-05-02
CN105555761B (zh) 2018-12-11
MX2016001200A (es) 2016-08-17
PH12016500197A1 (en) 2016-05-02
CA2919624C (en) 2018-07-24
US20160176816A1 (en) 2016-06-23
JP6109425B2 (ja) 2017-04-05
KR20150014673A (ko) 2015-02-09
ES2710389T3 (es) 2019-04-24
SG11201600624RA (en) 2016-03-30
BR112016001746A8 (pt) 2020-01-21
IL243830B (en) 2019-07-31
AU2014297144A1 (en) 2016-03-03
TR201901449T4 (tr) 2019-02-21
WO2015016511A1 (ko) 2015-02-05
IL243830A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
IN2012DN02968A (uk)
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
CA2917096C (en) Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
CA2891358C (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
FI3406609T3 (fi) Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina
WO2011051490A3 (en) Heterocyclic derivatives
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
WO2011110876A8 (en) Novel salts for the manufacture of pharmaceutical compositions
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
MX2014004479A (es) Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
WO2012066578A3 (en) Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
WO2007048070A3 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
PH12018500533A1 (en) Pyrazolyl-substituted heteroaryls and their use as medicaments
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MD20150023A2 (ro) Piridinone biciclice noi
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
EA201891261A1 (ru) Фармацевтическая композиция, содержащая производные глутаримидов, их применение для лечения эозинофильных заболеваний
WO2010084402A3 (en) Heterocyclic compounds as phosphodiesterase inhibitors
AR078552A1 (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
BR112017000584A2 (pt) inibidores da aldosterona sintase
UA116480C2 (uk) Похідна біфенілу та спосіб її одержання
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).